Literature DB >> 1885079

Proliferative activity of neuroendocrine tumours of the gastroenteropancreatic endocrine system: DNA flow cytometric and immunohistological investigations.

A von Herbay1, B Sieg, G Schürmann, W J Hofmann, M Betzler, H F Otto.   

Abstract

The proliferative activity of 16 tumour specimens from 13 patients with neuroendocrine tumours of the gastroenteropancreatic endocrine system was studied by DNA flow cytometry and immunohistology for the nuclear Ki67 proliferation antigen. Equivalent results were obtained with both methods, which showed the proliferative activity of gastroenteropancreatic neuroendocrine tumours to be heterogeneous. In four malignant small intestinal carcinoids and one extravisceral carcinoid localised in the retroperitoneum the percentage (index) of proliferating tumour cells as measured by DNA flow cytometry ranged from 2.9 to 36.2% corresponding to low, moderate, or high proliferative activity. In four malignant pancreatic endocrine tumours and their metastases indices ranged from 8.7 to 18.3%, corresponding to low, moderate, or high proliferative activity. In four benign pancreatic endocrine tumours indices ranged from 4.3 to 7.7%, all corresponding to low proliferative activity. This heterogeneity of proliferative activity may in part explain the heterogeneous results reported of chemotherapy treatment. As chemotherapy of tumours is largely affected by favourable cell cycling kinetics, individual diagnostic investigations of the proliferative activity of these neuroendocrine tumours may be of value for identifying patients suitable for this treatment.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1885079      PMCID: PMC1378969          DOI: 10.1136/gut.32.8.949

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  13 in total

Review 1.  The clinical assessment of proliferation and growth in human tumours: evaluation of methods and applications as prognostic variables.

Authors:  C M Quinn; N A Wright
Journal:  J Pathol       Date:  1990-02       Impact factor: 7.996

Review 2.  [Culture of gastroenteropancreatic endocrine tumors: current contributions and future prospects].

Authors:  L Elouaer-Blanc; M Mignon; M J Lewin
Journal:  Gastroenterol Clin Biol       Date:  1988 Jun-Jul

Review 3.  Chemotherapy of endocrine malignancies: a review.

Authors:  L K Kvols; M Buck
Journal:  Semin Oncol       Date:  1987-09       Impact factor: 4.929

4.  Flow cytometry of DNA content and other indicators of proliferative activity.

Authors:  H M Shapiro
Journal:  Arch Pathol Lab Med       Date:  1989-06       Impact factor: 5.534

5.  Endocrine tumors--special problems in diagnosis and management.

Authors:  E L Mazzaferri; T M O'Dorisio
Journal:  Semin Oncol       Date:  1987-09       Impact factor: 4.929

Review 6.  The cell cycle.

Authors:  R Baserga
Journal:  N Engl J Med       Date:  1981-02-19       Impact factor: 91.245

7.  Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67.

Authors:  J Gerdes; H Lemke; H Baisch; H H Wacker; U Schwab; H Stein
Journal:  J Immunol       Date:  1984-10       Impact factor: 5.422

8.  Flow microfluorometric deoxyribonucleic acid (DNA) analysis supplementing routine histopathologic diagnosis of biopsy specimens.

Authors:  D Haag
Journal:  Lab Invest       Date:  1980-01       Impact factor: 5.662

9.  Medical treatment and long-term survival in a prospective study of 84 patients with endocrine pancreatic tumors.

Authors:  B Eriksson; B Skogseid; G Lundqvist; L Wide; E Wilander; K Oberg
Journal:  Cancer       Date:  1990-05-01       Impact factor: 6.860

Review 10.  Pancreatic endocrine tumors.

Authors:  G Klöppel; P U Heitz
Journal:  Pathol Res Pract       Date:  1988-04       Impact factor: 3.250

View more
  8 in total

1.  Immunohistochemical investigation of F344/N rat islet cell tumors from national toxicology program studies.

Authors:  Christopher Koivisto; Gordon P Flake; Holly Kolenda-Roberts; Tiwanda Masinde; Grace E Kissling; Robert C Sills; Mark J Hoenerhoff
Journal:  Toxicol Pathol       Date:  2012-04-03       Impact factor: 1.902

Review 2.  Ki67 labeling index: assessment and prognostic role in gastroenteropancreatic neuroendocrine neoplasms.

Authors:  Günter Klöppel; Stefano La Rosa
Journal:  Virchows Arch       Date:  2017-11-13       Impact factor: 4.064

3.  Increased expression of CD44v6 in endocrine pancreatic tumours but not in midgut carcinoid tumours.

Authors:  B Terris; J F Fléjou; S Dubois; P Ruszniewski; J Y Scoazec; J Belghiti; F Potet; P Bernades; M Mignon; D Hénin
Journal:  Clin Mol Pathol       Date:  1996-08

4.  Comparison of WHO Classifications (2004, 2010), the Hochwald grading system, and AJCC and ENETS staging systems in predicting prognosis in locoregional well-differentiated pancreatic neuroendocrine tumors.

Authors:  Ta-Chiang Liu; Nicholas Hamilton; William Hawkins; Feng Gao; Dengfeng Cao
Journal:  Am J Surg Pathol       Date:  2013-06       Impact factor: 6.394

Review 5.  Predicting prognosis in gastroentero-pancreatic neuroendocrine tumors: an overview and the value of Ki-67 immunostaining.

Authors:  Mina Jamali; Runjan Chetty
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

6.  Proliferation Markers and Their Uses in the Study of Endocrine Tumors.

Authors:  Giuseppe Pelosi; Giuseppe Zamboni
Journal:  Endocr Pathol       Date:  1996       Impact factor: 3.943

7.  Neuroendocrine tumors involving the gastroenteropancreatic tract: a clinicopathological evaluation of 773 cases.

Authors:  Bruna Estrozi; Carlos E Bacchi
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

8.  Sildenafil potentiates the antitumor activity of cisplatin by induction of apoptosis and inhibition of proliferation and angiogenesis.

Authors:  Mona Mohamed El-Naa; Mohamed Othman; Sheren Younes
Journal:  Drug Des Devel Ther       Date:  2016-11-16       Impact factor: 4.162

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.